STARD 2015: How to Report Diagnostic Accuracy Studies with Clarity and Rigor

Introduction

Diagnostic tests form the cornerstone of clinical reasoning. But understanding whether a test is truly accurate requires high-quality research—research that is not only methodologically sound but also transparently reported. This is where STARD—STAndards for Reporting Diagnostic Accuracy Studies—steps in.

STARD 2015 is a reporting guideline, not a quality checklist. It ensures that authors provide sufficient information for readers, peer reviewers, and decision-makers to judge the trustworthiness and applicability of a study. In this article, we’ll walk through the full logic of the STARD checklist: what each item means, why it matters, and how to implement it, using novel examples for clarity.

---

🧩 1. What is STARD, and Why Does It Matter?

Core Purpose:

• Promote transparency and completeness in reporting diagnostic accuracy studies.
• Help users identify bias, applicability, and methodologic strengths/weaknesses.

What It Is Not:

• STARD is not a tool to appraise study quality (like QUADAS-2).
• It does not tell you how to conduct a study—but rather how to report it.

Problem Addressed:

• Many diagnostic studies omit key data on methods, patients, or test interpretation—leading to misleading or irreproducible findings.

---

🧠 2. Key Concepts in Diagnostic Accuracy Studies

• Diagnostic accuracy is not fixed; it varies across settings, populations, and test thresholds.
• Bias can be introduced by choices in:
  • Study design (e.g., cross-sectional vs. case-control)
  • Data collection (e.g., blinding, verification)
  • Analysis methods (e.g., handling indeterminate results)

---

🧾 3. The STARD 2015 Checklist: 30 Reporting Items

Grouped across 7 domains, the STARD checklist guides the researcher from title to funding:

A. Title & Abstract (Items 1–2)

• Clearly state that the study is a diagnostic accuracy study.
• Include key metrics like sensitivity, specificity, PPV, NPV, and AUC.

Example: “Evaluation of Saliva Antigen Test Accuracy for COVID-19 Detection: A Prospective Cross-Sectional Study”

B. Introduction (Items 3–4)

• Item 3: Give clinical context, including:
  • Intended use (screening, monitoring, staging)
  • Clinical role (triage, add-on, replacement)
• Item 4: State objectives and hypotheses:
  • Is the test being compared against another?
  • Are there predefined accuracy thresholds?

C. Methods (Items 5–18)

Study Design (Item 5)

• Specify if data collection was prospective or retrospective.

Participants (Items 6–9)

• Eligibility criteria must match the test's intended use.
• Clarify recruitment strategy (e.g., consecutive sampling).
• Report setting and dates to assess external validity.

Example: Recruited all adult outpatients presenting with suspected UTI at 3 urban clinics over 12 months.

Test Methods (Items 10–13)

• Describe both index and reference tests in enough detail for replication.
• Report who interpreted the tests and whether they were blinded.
• State the rationale for reference standard selection.

Cut-offs (Items 12a–12b)

• Pre-specify thresholds to avoid overfitting.
• Avoid choosing cut-offs based solely on maximizing AUC after seeing data.

Analysis (Items 14–18)

• Describe statistical methods for calculating Se/Sp, likelihood ratios, etc.
• Clarify how indeterminate or missing data were handled.
• Report whether sample size was calculated a priori and how.

D. Results (Items 19–25)

Flow Diagram (Item 19)

• Use STARD-style flow charts showing inclusion/exclusion.

Participant Characteristics (Items 20–21)

• Report demographics, disease severity spectrum, and alternative diagnoses in those without disease.

Timing (Item 22)

• Describe time interval between tests—important for diseases that change rapidly (e.g., infectious disease).

Data Presentation (Items 23–24)

• Include 2×2 cross-tabulations and confidence intervals for metrics.

Harms (Item 25)

• Report any adverse effects from tests (e.g., radiation from CT).

E. Discussion (Items 26–27)

• Study limitations: Reflect on biases, generalizability, and uncertainty.
• Implications for practice: Should the test replace current practice? For whom?

F. Other Information (Items 28–30)

• State registration number, protocol availability, and funding sources.

---

📌 Key Pitfalls STARD Helps Prevent

---

🔍Clinical Example: Applying STARD

Imagine evaluating a novel blood biomarker to detect early-stage pancreatic cancer. A good STARD-compliant report would:

• Recruit patients based on clinical presentation (e.g., unexplained weight loss + epigastric pain).
• Describe how blood samples were collected, who processed them, and who interpreted the results.
• Use endoscopic ultrasound with biopsy as the reference standard and explain why.
• Clearly state the cut-off value used to classify the biomarker as positive.
• Report 2×2 tables and CI for all diagnostic metrics.
• Describe whether pathologists were blinded to the blood test result.

---

✅ Key Takeaways

• STARD 2015 ensures that diagnostic accuracy studies are transparent, reproducible, and interpretable.
• Proper reporting improves the credibility and clinical utility of your findings.
• The checklist supports a methodologically sound narrative—one that tells the full story of your study.
• It aligns well with bias avoidance (see: QUADAS-2) and strengthens peer-review defense.